NextCure, Inc. NXTC
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
NextCure, Inc. (NXTC) is a healthcare company listed in the US with a market value of about $29M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -56%.
About NextCure
NextCure is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 23% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $22M | $6M | — |
| Net income | -$56M | -$56M | -$63M | -$75M | -$69M | -$37M | -$34M | -$23M |
| Free cash flow | — | -$41M | -$54M | -$56M | -$60M | -$52M | -$39M | $5M |
| EPS (diluted) | $-19.65 | $-23.88 | $-27.00 | $-32.28 | $-30.12 | $-15.96 | $-25.80 | $-199.68 |
| Net margin | — | — | — | — | — | -163.6% | -531.5% | — |
| ROIC | -113.5% | -66.1% | -44.1% | -34.3% | -23.9% | -11.0% | -9.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does NextCure pay a dividend?
Not currently.
Is NextCure a good stock to buy?
We do not give buy or sell advice. NextCure scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.